The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial

Journal:

Nature Communications

Published:

2026-05-11

DOI:

10.1038/s41467-026-72541-2

Affiliations:

12

Authors:

18

Go to article

Institutions	Authors	Share
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	4.000000	0.22
TransThera Sciences (Nanjing), China	4.000000	0.22
Henan Cancer Hospital, ZZU, China	2.000000	0.11
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, China	2.000000	0.11
Shandong Cancer Hospital, China	1.000000	0.06
Drum Tower Hospital, China	1.000000	0.06
Hunan Cancer Hospital, China	1.000000	0.06
Peking University Third Hospital (PUTH), PKUHSC, China	1.000000	0.06
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.06
TransThera Sciences (US), United States of America (USA)	1.000000	0.06

Interested in Oncology and Carcinogenesis?